Pascal Deschatelets - 09 Jun 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: APLS
Reported as of: 09 Jun 2025
Net transaction value: +$1,599,675
SEC form: 4
Accepted by SEC: 11 Jun 2025, 16:19:13 UTC
Prior SEC filing: 22 May 2025
Next SEC filing: 15 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets

Key filing fact

Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 11 Jun 2025.

Key facts

This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2025, 16:19.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: +$1,599,675.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001657720 Primary reporting owner

Deschatelets Pascal

Relationship: Chief Scientific Officer
Address: C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM
Signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Signature date: 11 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $1,599,675
Shares: +82,500
Change %
Price: $19.39
Shares after: 82,500
Date: 09 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 82,500
Exercise price: $19.39
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This represents stock option award granted on June 9, 2025, which will vest over a two-year period. Specifically, 50% of the options will vest on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service.